Vasculitis & polymyalgia rheumatica
Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study
Authors' conclusion
ADA combined with GCs and MTX may be more efficacious than TCZ combined with GCs and MTX among patients with active and severe TAK.
Study context
- Population
- Patients with active and severe TAK
- Participants
- 40 patients
- Comparison
- ADA vs tocilizumab (TCZ), each combined with glucocorticoids (GCs) and MTX
- ADAn = 21
- TCZn = 19reference
- Primary endpoint
- Efficacy rate (ER)
- Follow-up
- 6 months
Methodological detailsopen-label
- Open-label
Primary result
As reported in the abstract
ER
P = 0.02
Secondary outcomes
GC dose ≤10 mg/day · 6 months
P = 0.83
Relapse rate · first 12 months
P = 0.96
- Efficacy rate (ER) at 9 and 12 months
- P > 0.05
ER, per-protocol set · 6 months
- Similar direction of effect in the per-protocol set
- 89.47% vs 62.50%, P = 0.06
GC dose ≤10 mg/day · 6 months
- Similar between the ADA and TCZ groups
ER at 9 and 12 months
- Similar between the two groups
Relapse rate · first 12 months
- Comparable between the two groups
Safety
Adverse event incidence · first 12 months
P = 0.55
Original publication
Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study. Rheumatology (Oxford). Published 4 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →